CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Background: The therapeutic efficacy of chimeric antigen receptor (CAR) T-cells targeting CD19 has been illustrated in the treatment of diffuse large B-cell lymphoma (DLBCL). However, there is a 21–35% relapse rate after anti-CD19 CAR T-cell induced remission. In addition, CAR T-cell therapy has sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Sanfang, Zhou, Xuan, Guo, Zhenling, Huang, Rui, Yue, Chunyan, He, Yanjie, Li, Meifang, Chen, Yiran, Liu, YuChen, Chang, Lung-ji, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904344/
https://www.ncbi.nlm.nih.gov/pubmed/31867275
http://dx.doi.org/10.3389/fonc.2019.01350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904344/
https://www.ncbi.nlm.nih.gov/pubmed/31867275
http://dx.doi.org/10.3389/fonc.2019.01350

Ejemplares similares